hydroxychloroquine has been researched along with Benign Neoplasms in 68 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD)." | 7.72 | Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. ( Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003) |
| "It is a kind of cytokine storm, which involves increased activity of TNF-α, IL-1, IL-6, and INF-γ." | 5.62 | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. ( Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A, 2021) |
| " Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases." | 4.98 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. ( Koudriavtseva, T; Plantone, D, 2018) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD)." | 3.72 | Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. ( Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003) |
| "We then emphasize how autophagy and cancer cells interacting with one another is a promising therapeutic target in cancer treatment." | 3.01 | Recent Update and Drug Target in Molecular and Pharmacological Insights into Autophagy Modulation in Cancer Treatment and Future Progress. ( Islam, M; Kim, B; Parvez, MAK; Rahman, MA; Rahman, MS; Saikat, ASM, 2023) |
| "Hydroxychloroquine (HCQ) is a unique class of medications that has been widely utilized for the treatment of cancer." | 3.01 | Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation. ( Chang, SK; Chellappan, DK; Dua, K; Gan, SH; Goh, BH; Khaw, KY; Kong, CK; Lai-Foenander, AS; Lee, WL; Low, LE; Ming, LC; Ong, YS; Siew, WS; Singh, SK; Siva, SP; Tey, BT; Wu, Y; Yap, WH, 2023) |
| " Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization." | 2.94 | A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. ( Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS, 2020) |
| "While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy." | 2.82 | Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review. ( Al-Zeidaneen, SA; Algwaiz, GF; Karim, NA; Mohsen, S; Nasef, N; Sobash, PT, 2022) |
| " Treatment-related adverse events (AE) included grade 1 to 2 nausea, diarrhea, fatigue, weight loss, anemia, and elevated creatinine." | 2.79 | Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. ( Amaravadi, RK; Carew, JS; Curiel, TJ; Davis, LE; Espitia, CM; Giles, FJ; Mahalingam, D; Mita, AC; Mita, M; Nawrocki, ST; Sarantopoulos, J; Wood, L, 2014) |
| "Hydroxychloroquine was the most frequently used drug for COVID-19." | 2.72 | Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review. ( Kumar Gupta, A; Meena, JP; Mohan Pandey, R; Ram Jat, K; Seth, R; Tanwar, P, 2021) |
| "Given that CQ loses its anticancer activity in acidic and hypoxic environment within a tumor, novel CQ analogs and/or their formulations are under active investigation to improve their physicochemical properties and biological activity." | 2.72 | Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy. ( Fong, W; To, KKW, 2021) |
| "Antimalarials might reduce the risk of cancer in SLE among the Asian population (RR = 0." | 2.72 | Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies. ( Cao, NW; Chu, XJ; Li, BZ; Li, XB; Wang, H; Ye, DQ; Yu, SJ; Zhou, HY, 2021) |
| "However, the link between some anticancer mechanisms, clinical efficacy and pharmacological safety has not yet been fully defined." | 2.72 | Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. ( Bezerra, DP; Ferreira, JRO; Ferreira, PMP; Militão, GCG; Sousa, RWR, 2021) |
| "This is also true with regards to cancer treatments and screening." | 2.66 | Cancer therapy and treatments during COVID-19 era. ( Abrams, SL; Akula, SM; Basecke, J; Blalock, WL; Candido, S; Cervello, M; Cocco, L; Follo, MY; Lerpiriyapong, K; Libra, M; Martelli, AM; McCubrey, JA; Montalto, G; Notarbartolo, M; Piazzi, M; Ramazzotti, G; Ratti, S; Steelman, LS, 2020) |
| "Autophagy serves a dichotomous role in cancer and recent advances have helped delineate the appropriate settings where inhibiting or promoting autophagy may confer therapeutic efficacy in patients." | 2.53 | Emerging strategies to effectively target autophagy in cancer. ( Amaravadi, RK; Rebecca, VW, 2016) |
| "Herein, we review the effects of anti-cancer agents that impact metabolism administered concurrently with autophagy inhibitors on immune cells and consider the implications for patient response to therapy." | 2.48 | Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. ( Hughson, LR; Lum, JJ; Poon, VI; Schlie, K; Townsend, KN; Westerback, A, 2012) |
| "The overall risk of malignancy in patients with RA is decreased relative to in the general population." | 1.91 | Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea. ( Ko, KM; Moon, SJ, 2023) |
| "It is a kind of cytokine storm, which involves increased activity of TNF-α, IL-1, IL-6, and INF-γ." | 1.62 | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. ( Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A, 2021) |
| "Most cancers were diagnosed in SLE patients with an age 40~50 years." | 1.56 | [Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer]. ( Guo, JY; Li, JY; Li, TF; Liu, SY; Liu, XJ; Niu, CZ; Ren, ZG; Xuan, YY, 2020) |
| "It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments." | 1.56 | COVID-19 and lung cancer: risks, mechanisms and treatment interactions. ( Addeo, A; Friedlaender, A; Obeid, M, 2020) |
| "Mortality rate: 19/45 cancer patients vs 5586/42,450 (p = 0." | 1.56 | Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. ( Gullón, P; Lara, MÁ; López-Alfonso, A; Martín Marino, A; Obispo, B; Pangua, C; Pérez-Pérez, M; Rogado, J; Serrano-Montero, G, 2020) |
| "Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer." | 1.56 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. ( Bakouny, Z; Batist, G; Bekaii-Saab, T; Bilen, MA; Bouganim, N; Castellano, D; Choueiri, TK; de Lima Lopes, G; Del Prete, SA; Desai, A; Doroshow, DB; Egan, PC; Elkrief, A; Farmakiotis, D; Flora, D; Galsky, MD; Glover, MJ; Griffiths, EA; Grivas, P; Gulati, AP; Gupta, S; Hafez, N; Halfdanarson, TR; Hawley, JE; Hsu, CY; Hsu, E; Kasi, A; Khaki, AR; Kuderer, NM; Larroya, MB; Lemmon, CA; Lewis, C; Logan, B; Lyman, GH; Masters, T; McKay, RR; Mesa, RA; Mishra, S; Morgans, AK; Mulcahy, MF; Painter, CA; Panagiotou, OA; Peddi, P; Pennell, NA; Peters, S; Reynolds, K; Rini, BI; Rivera, DR; Rosen, LR; Rosovsky, R; Rubinstein, SM; Salazar, M; Schmidt, A; Shah, DP; Shah, SA; Shaya, JA; Shete, S; Shyr, Y; Steinharter, J; Stockerl-Goldstein, KE; Subbiah, S; Thompson, MA; Vinh, DC; Warner, JL; Wehbe, FH; Weissmann, LB; Wu, JT; Wulff-Burchfield, E; Xie, Z; Yeh, A; Yu, PP; Zhou, AY; Zubiri, L, 2020) |
| "Of the 51 SLE patients, thyroid cancer (14/51, 27." | 1.56 | The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. ( Guo, J; Li, J; Li, T; Liu, S; Ren, Z; Yu, Z, 2020) |
| "Among 2,186 U." | 1.56 | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. ( Arcobello, J; Bakouny, Z; Choueiri, TK; de Lima Lopes, G; Doroshow, DB; Egan, PC; Farmakiotis, D; Fecher, LA; Friese, CR; Galsky, MD; Goel, S; Grivas, P; Gupta, S; Halfdanarson, TR; Halmos, B; Hawley, JE; Hsu, CY; Khaki, AR; Kuderer, NM; Lee, BJ; Lemmon, CA; Lyman, GH; Mishra, S; Olszewski, AJ; Painter, CA; Panagiotou, OA; Pennell, NA; Peters, S; Puc, MM; Revankar, SG; Rini, BI; Rivera, DR; Rubinstein, SM; Schapira, L; Schmidt, A; Schwartz, GK; Shah, DP; Shah, SA; Shyr, Y; Thompson, MA; Warner, JL; Wu, JT; Xie, Z; Yeh, AC; Zhu, H, 2020) |
| "HCQ-HMSN-treated HCT116 colon cancer cells showed a 200-fold higher intracellular uptake of HCQ than that of free HCQ-treated cells, thereby effectively inhibiting the radiation-induced autophagy of cancer cells." | 1.56 | Hydroxychloroquine-loaded hollow mesoporous silica nanoparticles for enhanced autophagy inhibition and radiation therapy. ( Cheong, H; Cho, MH; Choi, Y; Lee, DE; Lee, SS; Li, Y, 2020) |
| " Arthralgias and arthritis are a common immune-related adverse event (IrAE), well described in the literature (Pardoll Nat Rev Cancer 12:252-264, 2012; Diesendruck and Benhar Drug Resist Updat 30:39-47, 2017; Cappelli et al." | 1.51 | Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. ( Basappa, NS; Chu, Q; Kolinsky, M; Lyddell, C; Roberts, J; Smylie, M; Walker, J; Ye, C, 2019) |
| "Hydroxychloroquine (HCQ) is a lysosomotropic autophagy inhibitor being used in over 50 clinical trials either alone or in combination with chemotherapy." | 1.48 | Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. ( Collins, KP; Gustafson, DL; Jackson, KM, 2018) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| "Twenty-five stage IV cancer patients were identified." | 1.42 | Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. ( Chi, KH; Chi, MS; Kao, SJ; Ko, HL; Lee, CY; Yang, KL, 2015) |
| "The incidence rates of cancer among biologics and nbDMARDs cohorts were 5." | 1.40 | The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. ( Chang, YT; Chen, CC; Chen, DY; Chen, YJ; Ho, HJ; Kuo, KN; Liu, HN; Shen, JL; Wu, CY, 2014) |
| "She also had developed anasarca two years prior to presentation." | 1.39 | Systemic lupus erythematosus and granulomatous lymphadenopathy. ( Dhakal, AK; Shah, SC; Shakya, A; Shakya, H; Shiva, RK; Shrestha, D, 2013) |
| "Autophagy inhibition is a novel cancer therapeutic strategy in the early stages of clinical trial testing." | 1.37 | Targeting autophagy addiction in cancer. ( Kimmelman, AC; Mancias, JD, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.94) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.47) | 29.6817 |
| 2010's | 26 (38.24) | 24.3611 |
| 2020's | 39 (57.35) | 2.80 |
| Authors | Studies |
|---|---|
| Li, XB | 1 |
| Cao, NW | 1 |
| Chu, XJ | 1 |
| Zhou, HY | 1 |
| Wang, H | 2 |
| Yu, SJ | 1 |
| Ye, DQ | 1 |
| Li, BZ | 1 |
| Shi, Y | 1 |
| Lin, G | 1 |
| Zheng, H | 1 |
| Mu, D | 1 |
| Chen, H | 1 |
| Lu, Z | 1 |
| He, P | 1 |
| Zhang, Y | 1 |
| Liu, C | 1 |
| Lin, Z | 1 |
| Liu, G | 1 |
| Mohsen, S | 1 |
| Sobash, PT | 1 |
| Algwaiz, GF | 1 |
| Nasef, N | 1 |
| Al-Zeidaneen, SA | 1 |
| Karim, NA | 1 |
| Qian, R | 1 |
| Cao, G | 1 |
| Su, W | 1 |
| Zhang, J | 1 |
| Jiang, Y | 1 |
| Song, H | 1 |
| Jia, F | 1 |
| Li, X | 1 |
| Wang, ZG | 1 |
| Zhu, H | 2 |
| Wen, HP | 1 |
| Ning, D | 1 |
| Liu, HY | 1 |
| Pang, DW | 1 |
| Liu, SL | 1 |
| Rahman, MA | 1 |
| Saikat, ASM | 1 |
| Rahman, MS | 1 |
| Islam, M | 1 |
| Parvez, MAK | 1 |
| Kim, B | 1 |
| Jain, V | 1 |
| Singh, MP | 1 |
| Amaravadi, RK | 7 |
| Phadatare, P | 1 |
| Debnath, J | 1 |
| Low, LE | 1 |
| Kong, CK | 1 |
| Yap, WH | 1 |
| Siva, SP | 1 |
| Gan, SH | 1 |
| Siew, WS | 1 |
| Ming, LC | 1 |
| Lai-Foenander, AS | 1 |
| Chang, SK | 1 |
| Lee, WL | 1 |
| Wu, Y | 1 |
| Khaw, KY | 1 |
| Ong, YS | 1 |
| Tey, BT | 1 |
| Singh, SK | 1 |
| Dua, K | 1 |
| Chellappan, DK | 1 |
| Goh, BH | 1 |
| Mehnert, JM | 1 |
| Kaveney, AD | 1 |
| Malhotra, J | 1 |
| Spencer, K | 1 |
| Portal, D | 1 |
| Goodin, S | 1 |
| Tan, AR | 1 |
| Aisner, J | 1 |
| Moss, RA | 1 |
| Lin, H | 1 |
| Bertino, JR | 1 |
| Gibbon, D | 1 |
| Doyle, LA | 1 |
| White, EP | 1 |
| Stein, MN | 1 |
| Guo, JY | 1 |
| Ren, ZG | 1 |
| Xuan, YY | 1 |
| Li, TF | 1 |
| Liu, XJ | 1 |
| Niu, CZ | 1 |
| Li, JY | 1 |
| Liu, SY | 1 |
| de Rojas, T | 1 |
| Pérez-Martínez, A | 1 |
| Cela, E | 1 |
| Baragaño, M | 1 |
| Galán, V | 1 |
| Mata, C | 1 |
| Peretó, A | 1 |
| Madero, L | 1 |
| Stroppa, EM | 1 |
| Toscani, I | 1 |
| Citterio, C | 1 |
| Anselmi, E | 1 |
| Zaffignani, E | 1 |
| Codeluppi, M | 1 |
| Cavanna, L | 2 |
| Dariya, B | 1 |
| Nagaraju, GP | 1 |
| Nawar, T | 1 |
| Morjaria, S | 1 |
| Kaltsas, A | 1 |
| Patel, D | 1 |
| Perez-Johnston, R | 1 |
| Daniyan, AF | 1 |
| Mailankody, S | 1 |
| Parameswaran, R | 1 |
| Addeo, A | 1 |
| Obeid, M | 1 |
| Friedlaender, A | 1 |
| Rogado, J | 2 |
| Obispo, B | 2 |
| Pangua, C | 1 |
| Serrano-Montero, G | 1 |
| Martín Marino, A | 1 |
| Pérez-Pérez, M | 1 |
| López-Alfonso, A | 1 |
| Gullón, P | 2 |
| Lara, MÁ | 2 |
| Kuderer, NM | 2 |
| Choueiri, TK | 2 |
| Shah, DP | 2 |
| Shyr, Y | 2 |
| Rubinstein, SM | 2 |
| Rivera, DR | 2 |
| Shete, S | 1 |
| Hsu, CY | 2 |
| Desai, A | 1 |
| de Lima Lopes, G | 2 |
| Grivas, P | 2 |
| Painter, CA | 2 |
| Peters, S | 2 |
| Thompson, MA | 2 |
| Bakouny, Z | 2 |
| Batist, G | 1 |
| Bekaii-Saab, T | 1 |
| Bilen, MA | 1 |
| Bouganim, N | 1 |
| Larroya, MB | 1 |
| Castellano, D | 1 |
| Del Prete, SA | 1 |
| Doroshow, DB | 2 |
| Egan, PC | 2 |
| Elkrief, A | 1 |
| Farmakiotis, D | 2 |
| Flora, D | 1 |
| Galsky, MD | 2 |
| Glover, MJ | 1 |
| Griffiths, EA | 1 |
| Gulati, AP | 1 |
| Gupta, S | 2 |
| Hafez, N | 1 |
| Halfdanarson, TR | 2 |
| Hawley, JE | 2 |
| Hsu, E | 1 |
| Kasi, A | 1 |
| Khaki, AR | 2 |
| Lemmon, CA | 2 |
| Lewis, C | 1 |
| Logan, B | 1 |
| Masters, T | 1 |
| McKay, RR | 1 |
| Mesa, RA | 1 |
| Morgans, AK | 1 |
| Mulcahy, MF | 1 |
| Panagiotou, OA | 2 |
| Peddi, P | 1 |
| Pennell, NA | 2 |
| Reynolds, K | 1 |
| Rosen, LR | 1 |
| Rosovsky, R | 1 |
| Salazar, M | 1 |
| Schmidt, A | 2 |
| Shah, SA | 2 |
| Shaya, JA | 1 |
| Steinharter, J | 1 |
| Stockerl-Goldstein, KE | 1 |
| Subbiah, S | 1 |
| Vinh, DC | 1 |
| Wehbe, FH | 1 |
| Weissmann, LB | 1 |
| Wu, JT | 2 |
| Wulff-Burchfield, E | 1 |
| Xie, Z | 2 |
| Yeh, A | 1 |
| Yu, PP | 1 |
| Zhou, AY | 1 |
| Zubiri, L | 1 |
| Mishra, S | 2 |
| Lyman, GH | 2 |
| Rini, BI | 2 |
| Warner, JL | 2 |
| Allahyari, A | 2 |
| Rahimi, H | 2 |
| Khadem-Rezaiyan, M | 2 |
| Mozaheb, Z | 2 |
| Seddigh-Shamsi, M | 2 |
| Bary, A | 2 |
| Kamandi, M | 2 |
| Azimi, SA | 1 |
| HasanAbadi, SE | 1 |
| Noferesti, A | 1 |
| Shariatmaghani, SS | 1 |
| Rafatpanah, H | 1 |
| Khatami, S | 1 |
| Imani, AJ | 1 |
| Mortazi, H | 1 |
| Nodeh, MM | 2 |
| Guo, J | 1 |
| Ren, Z | 1 |
| Li, J | 2 |
| Li, T | 1 |
| Liu, S | 1 |
| Yu, Z | 1 |
| Gougis, P | 1 |
| Fenioux, C | 1 |
| Funck-Brentano, C | 1 |
| Veyri, M | 1 |
| Gligorov, J | 1 |
| Solas, C | 1 |
| Spano, JP | 1 |
| Thorburn, A | 2 |
| Li, Y | 1 |
| Cho, MH | 1 |
| Lee, SS | 1 |
| Lee, DE | 1 |
| Cheong, H | 1 |
| Choi, Y | 1 |
| Davoudi-Monfared, E | 1 |
| Rahmani, H | 1 |
| Khalili, H | 1 |
| Hajiabdolbaghi, M | 1 |
| Salehi, M | 1 |
| Abbasian, L | 1 |
| Kazemzadeh, H | 1 |
| Yekaninejad, MS | 1 |
| McDonald, R | 1 |
| Lee, BJ | 1 |
| Arcobello, J | 1 |
| Fecher, LA | 3 |
| Friese, CR | 1 |
| Goel, S | 1 |
| Halmos, B | 1 |
| Olszewski, AJ | 1 |
| Puc, MM | 1 |
| Revankar, SG | 1 |
| Schapira, L | 1 |
| Schwartz, GK | 1 |
| Yeh, AC | 1 |
| Akula, SM | 1 |
| Abrams, SL | 1 |
| Steelman, LS | 1 |
| Candido, S | 1 |
| Libra, M | 1 |
| Lerpiriyapong, K | 1 |
| Cocco, L | 1 |
| Ramazzotti, G | 1 |
| Ratti, S | 1 |
| Follo, MY | 1 |
| Martelli, AM | 1 |
| Blalock, WL | 1 |
| Piazzi, M | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Notarbartolo, M | 1 |
| Basecke, J | 1 |
| McCubrey, JA | 1 |
| Liu, P | 1 |
| Zhao, L | 1 |
| Ferrere, G | 1 |
| Alves-Costa-Silva, C | 1 |
| Ly, P | 1 |
| Wu, Q | 1 |
| Tian, AL | 1 |
| Derosa, L | 1 |
| Zitvogel, L | 1 |
| Kepp, O | 1 |
| Kroemer, G | 1 |
| Colombi, D | 1 |
| Bodini, FC | 1 |
| Morelli, N | 1 |
| Silva, M | 1 |
| Milanese, G | 1 |
| Michieletti, E | 1 |
| Kiedrowski, M | 1 |
| Kapala, P | 1 |
| Kiedrowska, M | 1 |
| Skoczynska, A | 1 |
| Czerw, A | 1 |
| Deptała, A | 1 |
| Fong, W | 1 |
| To, KKW | 1 |
| Printz, C | 1 |
| Lorenzo-Vizcaya, A | 1 |
| Isenberg, D | 1 |
| Meena, JP | 1 |
| Kumar Gupta, A | 1 |
| Tanwar, P | 1 |
| Ram Jat, K | 1 |
| Mohan Pandey, R | 1 |
| Seth, R | 1 |
| Serrano, G | 1 |
| Ferreira, PMP | 1 |
| Sousa, RWR | 1 |
| Ferreira, JRO | 1 |
| Militão, GCG | 1 |
| Bezerra, DP | 1 |
| Vergoten, G | 1 |
| Bailly, C | 1 |
| Ataei Azimi, S | 1 |
| Zemorshidi, F | 1 |
| Urbina, F | 1 |
| Puhl, AC | 1 |
| Ekins, S | 1 |
| Ko, KM | 1 |
| Moon, SJ | 1 |
| Chude, CI | 1 |
| Levy, JMM | 1 |
| Towers, CG | 1 |
| Collins, KP | 1 |
| Jackson, KM | 1 |
| Gustafson, DL | 1 |
| Plantone, D | 1 |
| Koudriavtseva, T | 1 |
| Petri, M | 1 |
| Magder, LS | 1 |
| Park, K | 1 |
| Bishop, E | 1 |
| Bradshaw, TD | 1 |
| Zhan, L | 1 |
| Wei, B | 1 |
| Xu, R | 1 |
| Ji, Z | 1 |
| Xu, C | 1 |
| Zhu, J | 1 |
| Roberts, J | 1 |
| Smylie, M | 1 |
| Walker, J | 1 |
| Basappa, NS | 1 |
| Chu, Q | 1 |
| Kolinsky, M | 1 |
| Lyddell, C | 1 |
| Ye, C | 1 |
| Shrestha, D | 1 |
| Dhakal, AK | 1 |
| Shiva, RK | 1 |
| Shakya, A | 1 |
| Shah, SC | 1 |
| Shakya, H | 1 |
| Poklepovic, A | 1 |
| Gewirtz, DA | 1 |
| Mahalingam, D | 1 |
| Mita, M | 1 |
| Sarantopoulos, J | 1 |
| Wood, L | 1 |
| Davis, LE | 3 |
| Mita, AC | 1 |
| Curiel, TJ | 1 |
| Espitia, CM | 1 |
| Nawrocki, ST | 1 |
| Giles, FJ | 1 |
| Carew, JS | 1 |
| Rangwala, R | 2 |
| Chang, YC | 2 |
| Hu, J | 1 |
| Algazy, KM | 1 |
| Evans, TL | 2 |
| Schuchter, LM | 2 |
| Torigian, DA | 1 |
| Panosian, JT | 1 |
| Troxel, AB | 2 |
| Tan, KS | 2 |
| Heitjan, DF | 2 |
| DeMichele, AM | 2 |
| Vaughn, DJ | 1 |
| Redlinger, M | 1 |
| Alavi, A | 1 |
| Kaiser, J | 2 |
| Pontiggia, L | 2 |
| O'Dwyer, PJ | 2 |
| Leone, R | 1 |
| Kramer, A | 1 |
| Rodgers, G | 1 |
| Gallagher, M | 1 |
| Piao, S | 1 |
| Nathanson, KL | 1 |
| Wu, CY | 1 |
| Chen, DY | 1 |
| Shen, JL | 1 |
| Ho, HJ | 1 |
| Chen, CC | 1 |
| Kuo, KN | 1 |
| Liu, HN | 1 |
| Chang, YT | 1 |
| Chen, YJ | 1 |
| Uutela, T | 1 |
| Kautiainen, H | 1 |
| Järvenpää, S | 1 |
| Salomaa, S | 1 |
| Hakala, M | 1 |
| Häkkinen, A | 1 |
| Rebecca, VW | 1 |
| Chi, KH | 1 |
| Ko, HL | 1 |
| Yang, KL | 1 |
| Lee, CY | 1 |
| Chi, MS | 1 |
| Kao, SJ | 1 |
| Shi, TT | 1 |
| Yu, XX | 1 |
| Yan, LJ | 1 |
| Xiao, HT | 1 |
| Lippincott-Schwartz, J | 1 |
| Yin, XM | 1 |
| Weiss, WA | 1 |
| Takebe, N | 1 |
| Timmer, W | 1 |
| DiPaola, RS | 1 |
| Lotze, MT | 1 |
| White, E | 1 |
| Garber, K | 1 |
| Mancias, JD | 1 |
| Kimmelman, AC | 1 |
| Townsend, KN | 1 |
| Hughson, LR | 1 |
| Schlie, K | 1 |
| Poon, VI | 1 |
| Westerback, A | 1 |
| Lum, JJ | 1 |
| Kim, HA | 1 |
| Choi, HJ | 1 |
| Baek, HJ | 1 |
| Lim, MJ | 1 |
| Park, W | 1 |
| Lee, J | 1 |
| Choi, SJ | 1 |
| Yoon, BY | 1 |
| Choi, ST | 1 |
| Song, JS | 1 |
| Koh, BR | 1 |
| Suh, CH | 1 |
| Khoury, H | 1 |
| Trinkaus, K | 1 |
| Zhang, MJ | 1 |
| Adkins, D | 1 |
| Brown, R | 1 |
| Vij, R | 1 |
| Goodnough, LT | 1 |
| Ma, MK | 1 |
| McLeod, HL | 1 |
| Shenoy, S | 1 |
| Horowitz, M | 1 |
| Dipersio, JF | 1 |
| Turpie, AG | 1 |
| Paulus, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Immunological Responses of COVID-19 Vaccination in Cancer Patients on Chemotherapy: a Pilot Study[NCT05238467] | 42 participants (Actual) | Observational | 2021-05-21 | Completed | |||
| Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey[NCT04733729] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2020-03-01 | Recruiting | |||
| The COVID-19 and Cancer Consortium (CCC19) Registry[NCT04354701] | 19,275 participants (Actual) | Observational [Patient Registry] | 2020-03-17 | Active, not recruiting | |||
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
23 reviews available for hydroxychloroquine and Benign Neoplasms
| Article | Year |
|---|---|
Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.
Topics: Antimalarials; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Neoplasms; Prospective Stu | 2021 |
Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review.
Topics: Autophagy; Chloroquine; Humans; Hydroxychloroquine; Neoplasms; United States | 2022 |
Recent Update and Drug Target in Molecular and Pharmacological Insights into Autophagy Modulation in Cancer Treatment and Future Progress.
Topics: Antineoplastic Agents; Autophagy; Chloroquine; Humans; Hydroxychloroquine; Neoplasms | 2023 |
Recent advances in targeting autophagy in cancer.
Topics: Autophagy; Humans; Hydroxychloroquine; Neoplasms | 2023 |
Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation.
Topics: Humans; Hydroxychloroquine; Nanotechnology; Neoplasms; Tumor Microenvironment | 2023 |
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Comorbid | 2020 |
Crosstalk between autophagy and apoptosis: Mechanisms and therapeutic implications.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Relat | 2020 |
Cancer therapy and treatments during COVID-19 era.
Topics: Angiotensin-Converting Enzyme 2; Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Comorbidi | 2020 |
Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Chemotherapy, Adjuvant; Chloroquine; Drug Repo | 2021 |
Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review.
Topics: Antimalarials; Child; COVID-19; Critical Care; Hematologic Neoplasms; Humans; Hydroxychloroquine; Ne | 2021 |
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.
Topics: Antineoplastic Agents; Autophagy; Chloroquine; Clinical Trials as Topic; Drug Resistance, Neoplasm; | 2021 |
Recent advances in drug repurposing using machine learning.
Topics: Alzheimer Disease; Antineoplastic Agents; Antiviral Agents; Clemastine; Computational Biology; COVID | 2021 |
Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors.
Topics: Animals; Antimalarials; Antineoplastic Agents; Autophagy; Clinical Trials as Topic; Humans; Hydroxyc | 2017 |
Targeting autophagy in cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Chloroquine; Clinical Trials as Topic; | 2017 |
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic | 2018 |
Autophagy modulation: a prudent approach in cancer treatment?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Clinical Trials as Topic; Humans | 2018 |
Autophagy therapeutics: preclinical basis and initial clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Survival; Chloroquine; Clin | 2018 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Da | 2018 |
Emerging strategies to effectively target autophagy in cancer.
Topics: Animals; Autophagy; Humans; Hydroxychloroquine; Neoplasms; Signal Transduction | 2016 |
Research progress of hydroxychloroquine and autophagy inhibitors on cancer.
Topics: Autophagy; Clinical Trials as Topic; Humans; Hydroxychloroquine; Neoplasms; Retina | 2017 |
Principles and current strategies for targeting autophagy for cancer treatment.
Topics: Animals; Antineoplastic Agents; Autophagy; Clinical Trials, Phase III as Topic; Combined Modality Th | 2011 |
Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
9 trials available for hydroxychloroquine and Benign Neoplasms
| Article | Year |
|---|---|
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Drug Mo | 2019 |
Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; Human | 2020 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbi | 2020 |
Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: study protocol for a randomized controlled trial.
Topics: Adolescent; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Iran; Neoplasms; Randomized Control | 2021 |
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Demograph | 2014 |
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose- | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazi | 2014 |
Nonsteroidal antiinflammatory drugs (NSAID) versus NSAID with hydroxychloroquine in treatment of chemotherapy-related arthropathy: open-label multicenter pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug | 2012 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
37 other studies available for hydroxychloroquine and Benign Neoplasms
| Article | Year |
|---|---|
Biomimetic nanoparticles blocking autophagy for enhanced chemotherapy and metastasis inhibition via reversing focal adhesion disassembly.
Topics: Animals; Antineoplastic Agents; Autophagy; Biomimetic Materials; Cadherins; Cell Line, Tumor; Cell M | 2021 |
Enhanced Sensitivity of Tumor Cells to Autophagy Inhibitors Using Fasting-Mimicking Diet and Targeted Lysosomal Delivery Nanoplatform.
Topics: Autophagy; Cell Line, Tumor; Fasting; Humans; Hydroxychloroquine; Lysosomes; Neoplasms | 2022 |
Inducing Autophagy and Blocking Autophagic Flux via a Virus-Mimicking Nanodrug for Cancer Therapy.
Topics: Apoptosis; Autophagy; Hydroxychloroquine; Lysosomes; Nanoparticles; Neoplasms | 2022 |
Lysosomal lipid peroxidation mediates immunogenic cell death.
Topics: Chloroquine; Humans; Hydroxychloroquine; Immunogenic Cell Death; Lipid Peroxidation; Lysosomes; Neop | 2023 |
[Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer].
Topics: Adult; China; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Neoplasms; Ris | 2020 |
COVID-19 infection in children and adolescents with cancer in Madrid.
Topics: Adolescent; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVI | 2020 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; | 2020 |
Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?
Topics: Adult; Aged; Betacoronavirus; Bone Marrow; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment | 2020 |
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coro | 2020 |
Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid.
Topics: Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Hu | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Topics: Aged; Antiviral Agents; Azithromycin; Betacoronavirus; Cause of Death; Comorbidity; Coronavirus Infe | 2020 |
The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; A | 2020 |
Hydroxychloroquine-loaded hollow mesoporous silica nanoparticles for enhanced autophagy inhibition and radiation therapy.
Topics: Animals; Autophagy; Humans; Hydroxychloroquine; Mice; Nanoparticles; Neoplasms; Silicon Dioxide | 2020 |
Cancer Progression Is Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Betacoronavirus; Clinical Decision-Making; Coro | 2020 |
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azithromycin; Cell Line, Tumor; Cisplatin; | 2020 |
COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Carcinoma, Squamous Cell; Coronaviru | 2021 |
Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19.
Topics: Autophagy; Cachexia; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Hum | 2021 |
Research shows racial disparity, mortality data for patients with cancer and COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Black or African American; COVID-19; COVID-19 Dr | 2021 |
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies; | 2021 |
Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Topics: Adenosine Monophosphate; Aged; Alanine; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; C | 2021 |
Binding of hydroxychloroquine and chloroquine dimers to palmitoyl-protein thioesterase 1 (PPT1) and its glycosylated forms: a computational approach.
Topics: Asparagine; Child; Chloroquine; Fatty Acids; Humans; Hydroxychloroquine; Membrane Proteins; Neoplasm | 2022 |
Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea.
Topics: Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Hydroxychloroquine; Incidence; Lung Neoplasms | 2023 |
Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.
Topics: Absorption, Physicochemical; Animals; Autophagy; Clinical Trials as Topic; Female; Humans; Hydroxych | 2018 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Enhanced bacterial cancer therapy with hydroxychloroquine liposomes.
Topics: Antineoplastic Agents; Bacteria; Bacterial Vaccines; Delayed-Action Preparations; Drug Liberation; H | 2018 |
Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2019 |
Systemic lupus erythematosus and granulomatous lymphadenopathy.
Topics: Antibodies, Antinuclear; Child; Connective Tissue Diseases; Diagnosis, Differential; Disease Progres | 2013 |
Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Clinical | 2014 |
The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2014 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Produc | 2015 |
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Re | 2015 |
Inducing indigestion: companies embrace autophagy inhibitors.
Topics: Animals; Antimalarials; Antineoplastic Agents; Autophagy; Cell Hypoxia; Cell Survival; Clinical Tria | 2011 |
Targeting autophagy addiction in cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Chloroquine; Genes, ras; Humans; Hydroxychloroquine; Mice | 2011 |
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation.
Topics: Adolescent; Adult; Antigens, CD; Bone Marrow Transplantation; Cause of Death; Enzyme Inhibitors; Gra | 2003 |
An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today.
Topics: Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyclophosphamide; Female; Gold; Humans; Hydroxychl | 1982 |